Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASA trial of adjuvant pegylated liposomal doxorubicin in older women with endocrine-nonresponsive breast cancer
NL-OMON31071Phase 3Withdrawn
- Sponsor
- International Breast Cancer Study Group
- Start
- Jun 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin, cyclophosphamide and methotrexate in breast cancer (4 arms), sponsored by International Breast Cancer Study Group. Primary endpoint: Breast cancer free interval. Planned start Jun 2007; status: withdrawn.
02
Drugs
pegylated liposomal doxorubicincyclophosphamidemethotrexate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON31071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31071.